Articles tagged with B Lymphocytes
A new $1.7 million NIH grant will support Carol Webb's research on the protein ARID3a and its role in lupus development and treatment. The study aims to identify genes controlled by ARID3a, understand how it disrupts the immune system, and test potential treatments.
Researchers found that people experiencing everyday discrimination have elevated levels of "exhausted" white blood cells, indicating chronic stress may hamper the immune system. This study suggests social experiences like discrimination shape immune health at the cellular level and contribute to biological aging.
Research reveals molecular interaction between environmental and genetic risk factors triggers MS. EBV and gene variants HLA-DR15 haplotype play key roles in disease onset.
Huimin Zhang, a UC Riverside assistant professor, has received a $150,000 grant to study the role of HELIOS in epigenetic regulation of T cell aging and TFH cell differentiation. Her research aims to understand how aging affects the immune system and develop new vaccines and therapies to restore immune vitality in older adults.
Australian scientists have discovered how T follicular helper cells tailor their behavior to different infections, paving the way for improved vaccine design and targeted therapies. The study sheds light on a molecular 'instruction manual' guiding antibody production and long-term immunity.
Researchers at Penn State College of Medicine discovered a new function of antibody-making B cells in response to flu infection. These cells produce a key signaling molecule called interleukin-1 beta, which is necessary for developing a robust immune response and forming optimal germinal centers.
A new DNA-based blood test using PhasED-Seq technology detects minimal residual disease (MRD) in B-cell malignancies, offering a powerful tool for early detection and monitoring treatment response. The assay demonstrates exceptional performance and high accuracy in detecting cancer cells in the bloodstream.
Neuro-immunologist Stephen Hauser has won the 2025 Breakthrough Prize in Life Sciences for his role in identifying the immune system's primary driver of damage to nerve cells in multiple sclerosis. His B-cell theory has led to the development of therapies that have transformed treatment, reducing relapses and improving prognosis.
Dr. Amit Bar-Or is awarded the 2025 John Dystel Prize for his contributions to neuroimmunology and precision medicine in multiple sclerosis research. His work has led to significant advancements in disease mechanisms, treatment approaches, and biomarker studies.
A study by Rockefeller University reveals that germinal centers suppress mutation during rapid proliferation and resume it after expansion, enabling efficient antibody production. This discovery may have broader implications for vaccine design and immune therapies.
Researchers have discovered that high-affinity B cells can avoid degrading functional antibodies by 'banking' successful mutations and 'cloning' advantageous traits. This mechanism may lead to the development of more effective vaccines against pathogens like HIV, which constantly mutates and hides key targets.
Researchers from Osaka University found that selenoproteins are essential for counteracting lipid peroxides and maintaining hematopoiesis in human cells. The study also showed that dietary Vitamin E can protect hematopoiesis and repair impaired B cell differentiation, providing potential strategies for fighting age-related diseases.
Researchers at Garvan Institute of Medical Research discovered how chronic hepatitis C infection leads to autoimmune disease by identifying 'rogue clone' B cells with harmful autoantibodies. The study found that a triad of genetic mutations is required for the autoimmune disease to develop, opening new paths for treatments.
Researchers developed a new super-resolution microscopic method to investigate the interactions of therapeutic antibodies with target molecules on tumour cells. The study reveals that all four antibodies crosslink CD20 molecules independently of type I or II classification, and that B cells take on a hedgehog shape after treatment.
The University of Surrey's research focuses on targeting mutated pathways with new drugs to treat rare conditions like immunodeficiencies. The team discovered that mTOR inhibitors can help restore normal B cell function.
A USC Stem Cell mouse study identifies a small subset of blood stem cells as the primary driver of immune aging. The researchers found that this subset overproduces innate immune cells, leading to an age-associated imbalance and increased disease risk. By targeting this subset, the study suggests a potential therapy to delay immune agi...
Researchers discover a molecular mechanism controlling PAX5, key regulator of B-cell maturation. Increasing SIRT7 activity may boost PAX5 levels in leukemic cells, inducing cell death.
Pro-B cells, a stage in B cell development, exhibit unusual plasticity when YY1 is knocked out. This enables them to generate T lineage cells, which help B cells produce antibodies. The study published in Genes & Development reveals the potential for regenerative medicine applications.
Researchers at IGTP have discovered a specific cellular pattern in regulatory B cells to monitor kidney transplant patients. This signature can help identify low-risk patients who may benefit from reduced immunosuppression and those at high risk who require closer monitoring.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Scientists identified two distinct patterns of B cell abnormalities, TiBA-0, TiBA-1, and TiBA-2, which are linked to an immunosuppressive effect and poorer treatment response. These biomarkers can be detected through a simple blood draw, enabling potential stratification of patients and personalized treatment.
A Mayo Clinic study found that people with monoclonal B-cell lymphocytosis (MBL) have a 92% elevated risk of developing melanoma. MBL is a precursor to chronic lymphocytic leukemia and also increases the risk of cancers originating in the lymphatic system and serious infections.
A team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination. They found that activated atypical B cells are the main responders to mRNA vaccines, providing a new way to assess vaccine response and underlying biology.
Scientists discovered that T follicular helper cells indirectly control the anti-influenza response, leading to less effective immunity. The study found that the current flu vaccine formulation could be improved by excluding internal proteins and targeting surface proteins.
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
Scientists from Hackensack Meridian Health have identified a new potential pathway for developing vaccines against tuberculosis by targeting marginal zone B (MZB) cells, a natural response to TB infection. The discovery suggests that boosting MZB cell activity could provide reliable and durable protection against the disease.
Patients with 18q deletion syndrome exhibit both cellular and humoral immunodeficiency, characterized by low immunoglobulin levels and impaired T-cell function. Regular testing for both cellular and humoral immunity can allow for early detection of combined immune deficiencies and improve clinical outcomes.
A study published in PNAS reveals that ETV5 enhances the expression of osteopontin, leading to the differentiation of T cells into follicular helper cells. In SLE patients, disease activity is proportional to ETV5 and osteopontin levels, suggesting a potential therapeutic target for treating lupus.
A Kobe University study finds that a new treatment for neuromyelitis optica spectrum disorder shifts the balance of immune cells, increasing anti-inflammatory signals. The discovery may enable clinicians to determine treatment effectiveness and move towards personalized medicine for autoimmune diseases.
Researchers have discovered that metabolism plays a crucial role in the balance between T and B cells, leading to autoimmune diseases. The study suggests that targeting the interaction between immune cells and metabolism could lead to more effective treatments for conditions like rheumatoid arthritis and lupus.
Researchers discovered how Epstein-Barr virus (EBV)-infected B cells contribute to multiple sclerosis (MS) inflammation and disease. A new treatment strategy targeting these problematic cells may offer a selectively cytotoxic approach to MS therapy.
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
Researchers found that abnormally active B cell metabolism causes an inflammatory immune response in individuals with Multiple Sclerosis (MS), leading to nerve damage and symptoms. Emerging BTK inhibitors alter this abnormal B cell respiration, stopping the signaling that leads to MS flare-ups.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.
Researchers at UC Riverside demonstrate a new vaccine strategy targeting a common viral genome part, eliminating the need for annual booster shots. The vaccine uses small RNA molecules to boost the immune system, making it safe for babies and those with weakened immunity.
Australian researchers have identified a previously unknown immune B memory cell that fails to produce high levels of antibodies against persistent infections. The discovery may lead to earlier intervention and prevention of chronic viral infections like HIV or hepatitis.
A large cohort study found that longer durations of exclusive breastfeeding were associated with a lower risk of childhood B-cell precursor-acute lymphoblastic leukemia. The study's results suggest potential biologic mechanisms underlying this association and inform the need for further research on preemptive interventions.
A recent literature review discusses the underlying mechanisms of type 2 diabetes, including insulin resistance and b-cell failure. The review also explores potential therapeutic strategies, such as replenishing and regenerating b-cells, pancreas transplants, and stem cell-derived b-cells.
Researchers have discovered a previously unknown mechanism behind immune tolerance, where B cells teach T cells to ignore the body's own proteins. This failure can lead to autoimmune diseases such as Multiple Sclerosis-like Neuromyelitis optica.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
A recent study published in Lancet Microbe suggests that immunocompromised patients are at higher risk for COVID infections, but prolonged infections lasting weeks to months are uncommon. The study found that specific conditions, such as B-cell cancers and autoimmune diseases, increase the risk of prolonged infections.
Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.
A comprehensive review of targeted therapies for lupus nephritis discusses the challenges of current treatments and proposes strategies to overcome obstacles. Recent advancements in B-cell targeting and alternative approaches such as CAR-T cells are highlighted.
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
Researchers found that vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of innate-like B cells producing antibody against N-acetyl-D-glucosamine (GlcNAc), reducing Type 1 diabetes risk. These GlcNAc-specific B-1 B cells aid in producing tolerance, facilitating efficient clearance of apoptotic beta cells...
Researchers at La Jolla Institute for Immunology and Massachusetts General Hospital mapped the genome to understand how IKAROS controls healthy B cell development. They found that IKAROS solves a big problem in B cell development by bringing together far-away genes through looping, leading to proper expression and antibody production.
Researchers have identified a common mutation in the transcription factor IRF4 that drives tumor cell development in Hodgkin's lymphoma. This mutation leads to the activation of disease-relevant genes, and blocking its effects could provide new therapeutic opportunities.
Researchers identified TLR9 as a key receptor in central tolerance, the process that eliminates self-reactive B cells. Depleting TLR9 impairs this process, leading to increased antibody production and autoimmune disease. Neutralizing CXCL4 may restore B cell tolerance, offering new therapeutic strategies.
Researchers at the Babraham Institute have discovered that the 3D organisation of DNA in B cells allows for genes far away from each other to come together during antibody generation. This finding has implications for understanding why antibody diversity declines with age and suggests potential interventions.
Researchers found that Epstein-Barr virus induces B cell growth transformation through the activation of the cancer-related gene IMPDH2, leading to uncontrolled proliferation. The study used primary B cells and found that inhibiting IMPDH2 can suppress post-transplant lymphoproliferative disorder (PTLD) development.
A new study reveals that breast milk contains a unique set of antibodies passed from mom to baby, which can vary significantly between mothers. This variability may explain why some infants develop life-threatening diseases like NEC, while others do not.
Researchers investigate MCL-1i-induced Mcl-1 protein accumulation and its implications in B-cell malignancies. The study reveals a complex mechanism contributing to MCL-1 protein stability upon treatment with MCL-1 inhibitors.
Researchers discovered a protein, C/EBPα, that accelerates B lymphocyte-to-macrophage conversion by interacting with PU.1. This epigenetic mechanism may be targeted for cancer research and treatment.
Scientists found that CXCL13-mediated recruitment of B cells helps predict response to immunotherapy treatment. This cooperation between T cells and B cells is associated with improved survival in patients treated with immunotherapy.
A team of researchers identified TIM-1 as a key player in regulating anti-tumor immunity in melanoma. By targeting TIM-1, the immune system can activate killer T cells to inhibit tumor growth. The study's findings have significant implications for developing new cancer therapies.
Researchers have developed an automated calling algorithm for determining B and T cell clonality from NGS data with greater sensitivity than previous models. The new model increases the assay's sensitivity in detecting clonality, allowing for more accurate diagnosis and monitoring of lymphoproliferative disorders.